Science Corporation PRIMA Retinal Implant: First Stargardt Disease Patient and the Path to BCI
Science Corporation has implanted its PRIMA vision-restoring chip in its first patient with Stargardt disease, an inherited form of macular degeneration. Founder Max Hodak, who co-founded Neuralink, told the TechCrunch Disrupt audience that the work is part of the company's route toward a new kind of brain-computer interface. The move extends a device mostly associated with age-related vision loss into a younger, rarer patient group.
What was implanted, and in whom
PRIMA is a subretinal implant, a tiny photovoltaic chip about 2 mm across that sits beneath the retina. A camera mounted on glasses captures the scene and projects it as infrared light onto the chip. The chip converts that light into electrical stimulation of the remaining retinal neurons.
Science Corporation took over the PRIMA program from Pixium Vision in 2025. Until now, the device was studied mainly in people who had lost central vision to advanced dry age-related macular degeneration. The first Stargardt patient marks the first time the company has put the chip into a different disease population. Details such as post-surgery visual outcomes have not been disclosed.
Why Stargardt disease is a logical next target
Stargardt disease is usually caused by mutations in the ABCA4 gene. Symptoms typically start in adolescence or early adulthood, and central vision deteriorates progressively as photoreceptors in the macula die. There is currently no approved treatment that restores lost sight.
That gives the condition something in common with dry AMD: the light-sensing cells in the center of the retina are gone, but parts of the downstream retinal circuitry remain. A prosthesis that replaces the photoreceptor function is a plausible fit for both. The difference is patient age. A younger recipient will live with an implant for decades, which raises the bar for long-term safety and durability data.
The BCI angle
Hodak left Neuralink in 2021 and founded Science to work on neural interfaces. At Disrupt he framed PRIMA as a step toward a novel BCI rather than a standalone product line.
The logic is reasonably clear. The retina is part of the central nervous system, and converting external signals into neural stimulation is the same core problem a BCI has to solve. A company that can get an implant through surgery, regulators and real-world use has accumulated the kind of clinical and manufacturing experience that brain-focused startups often lack. This reading is an inference from the company's stated direction, and Science has not published a detailed timeline for follow-on products.
How this compares with the rest of the field
Neuralink and similar companies have focused on electrodes that read or write signals in the brain, mostly for paralysis and communication. Science is pursuing a different order of operations: begin with a sensory prosthesis targeting a defined medical need, then build outward. If PRIMA reaches the market for AMD, the company would have revenue, a regulatory track record and a user base before it attempts more ambitious neural interfaces.
Previous retinal prostheses such as Argus II were limited by very low resolution and by company financial trouble, which left users without support. Sustained commercial backing is therefore as important as the technology, and it is one reason the corporate path matters.
What to watch
- Whether the first Stargardt patient reports meaningful improvement in central vision, and how that is measured.
- Whether Science opens a formal trial for inherited retinal conditions and what regulators require for the expanded use.
- Whether the company shows a concrete bridge from PRIMA to a brain-facing device, rather than only a stated ambition.
Takeaway
One implant is not evidence of efficacy. But it shows Science is willing to widen PRIMA's use beyond AMD while keeping its BCI strategy in view. The next data releases will indicate whether the retina is a realistic stepping stone to neural interfaces or only a separate medical-device business.
Comments
Post a Comment
Please read our comment policy before commenting.